rAAV9 combined with renal vein injection is optimal for kidney-targeted gene delivery: conclusion of a comparative study.
Effective gene therapy strategies for the treatment of kidney disorders remain elusive. We report an optimized kidney-targeted gene delivery strategy using recombinant adeno-associated virus (rAAV) administered via retrograde renal vein injection in mice. Renal vein injection of rAAV consistently resulted in superior kidney transduction compared with tail vein injection using as little as half the tail vein dose. We compared rAAV5, 6, 8 and 9, containing either green fluorescent protein (GFP) or luciferase reporter genes driven by the Cytomegalovirus promoter. We demonstrated that although rAAV6 and 8 injected via renal vein transduced the kidney, transgene expression was mainly restricted to the medulla. Transgene expression was systematically low after rAAV5 injection, attributed to T-cell immune response, which could be overcome by transient immunosuppression. However, rAAV9 was the only serotype that permitted high-transduction efficiency of both the cortex and medulla. Moreover, both the glomeruli and tubules were targeted, with a higher efficiency within the glomeruli. To improve the specificity of kidney-targeted gene delivery with rAAV9, we used the parathyroid hormone receptor 'kidney-specific' promoter. We obtained a more efficient transgene expression within the kidney, and a significant reduction in other tissues. Our work represents the first comprehensive and clinically relevant study for kidney gene delivery.
Department of Pediatrics, Division of Genetics, University of California, San Diego, La Jolla, CA, USA.
C J
CJ
Rocca
Department of Pediatrics, Division of Genetics, University of California, San Diego, La Jolla, CA, USA.
S N
SN
Ur
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA.
F
F
Harrison
Department of Pediatrics, Division of Genetics, University of California, San Diego, La Jolla, CA, USA.
S
S
Cherqui
D000818:Animals; D000229:Dependovirus / Q000235:genetics*; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors / Q000008:administration & dosage*; D007267:Injections; D007668:Kidney / Q000187:drug effects / Q000502:physiology; D008810:Mice, Inbred C57BL; D011401:Promoter Regions, Genetic; D044168:Receptor, Parathyroid Hormone, Type 1 / Q000235:genetics; D012082:Renal Veins / Q000187:drug effects*; D013623:Tail; D014161:Transduction, Genetic; D019076:Transgenes
D044168:Receptor, Parathyroid Hormone, Type 1